Publication: Identification of vinyl sulfone derivatives as egfr tyrosine kinase inhibitor: In vitro and in silico studies
Issued Date
2021-01-01
Resource Type
ISSN
14203049
Other identifier(s)
2-s2.0-85105164646
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Molecules. Vol.26, No.8 (2021)
Suggested Citation
Thitinan Aiebchun, Panupong Mahalapbutr, Atima Auepattanapong, Onnicha Khaikate, Supaphorn Seetaha, Lueacha Tabtimmai, Chutima Kuhakarn, Kiattawee Choowongkomon, Thanyada Rungrotmongkol Identification of vinyl sulfone derivatives as egfr tyrosine kinase inhibitor: In vitro and in silico studies. Molecules. Vol.26, No.8 (2021). doi:10.3390/molecules26082211 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/76380
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Identification of vinyl sulfone derivatives as egfr tyrosine kinase inhibitor: In vitro and in silico studies
Abstract
Epidermal growth factor receptor (EGFR), overexpressed in many types of cancer, has been proved as a high potential target for targeted cancer therapy due to its role in regulating proliferation and survival of cancer cells. In the present study, a series of designed vinyl sulfone derivatives was screened against EGFR tyrosine kinase (EGFR-TK) using in silico and in vitro studies. The molecular docking results suggested that, among 78 vinyl sulfones, there were eight compounds that could interact well with the EGFR-TK at the ATP-binding site. Afterwards, these screened compounds were tested for the inhibitory activity towards EGFR-TK using ADP-Glo™ kinase assay, and we found that only VF16 compound exhibited promising inhibitory activity against EGFR-TK with the IC50 value of 7.85 ± 0.88 nM. In addition, VF16 showed a high cytotoxicity with IC50 values of 33.52 ± 2.57, 54.63 ± 0.09, and 30.38 ± 1.37 µM against the A431, A549, and H1975 cancer cell lines, respectively. From 500-ns MD simulation, the structural stability of VF16 in complex with EGFR-TK was quite stable, suggesting that this compound could be a novel small molecule inhibitor targeting EGFR-TK.